Impaired glucose regulation
Conditions
Interventions
Group 2:Lifestyle+metformin intervention
Group 3:Lifestyle+Jinlida intervention
Sponsors
The First Affiliated Hospital of Harbin Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. According to the classification standard of glucose metabolism of WTO (1999), the subjects who had been diagnosed with IGR (given OGTT test) within 2 weeks before joining the group. IGR: impaired glucose regulation: IGR includes IFG or IGT or IFG + IGT IGT:FPG < 7.0mmol/L; 2hPG7.8 <= PG <= 11.1mmol/L IFG:6.1mmol/L <= FPG < 7.0mmol/L,2hPG < 7.8mmol/L. 2. Age: 18 years old <= 70 years old patients. 3. Subjects who have not used hypoglycemic drugs (including Chinese herbal medicines for lowering blood sugar) in the past 6 months. 4. Men or women who are not pregnant or breast-feeding and have no family planning in the next three years. 5. Body mass index: (BMI): 21kg / m2 <= BMI <= 32kg / m2.
Exclusion criteria
Exclusion criteria: 1. Patients who take drugs that affect glucose metabolism for the treatment of previous diseases; 2. Patients who took weight-loss drugs (including traditional Chinese Medicine) within six months and during the intervention period; 3. Patients taking three or more antihypertensive drugs at present; 4. Patients with diabetes mellitus (previous history of gestational diabetes is not included in the exclusion criteria); 5. To screen patients with acute myocardial infarction, grade III / iv2 congestive heart failure defined by the New York Heart Association, left ventricular ejection fraction = 160mmhg, or diastolic blood pressure >= 100mmhg); 7. Patients with impaired liver function have obvious clinical signs or symptoms of liver disease, acute or chronic hepatitis, ALT or ast level at screening visit is more than 3 times of the reference range; 8. Patients with renal insufficiency (EGFR < 45ml / min); 9. Patients who use ventilator; 10. Patients who are allergic to metformin or any of the excipients (such as povidone K30, magnesium stearate and hydroxypropylmethylcellulose); 11. Suffering from diseases that may cause tissue hypoxia (especially exacerbation of acute or chronic respiratory diseases). 12. Objects of acute intoxication and alcoholism; 13. Patients with severe chronic gastrointestinal diseases; 14. Patients with severe mental illness; 15. Patients with cancer in need of treatment in the past five years; 16. Patients with thyroid diseases not effectively controlled; 17. Pregnant or lactating women; 18. Patients who have participated in other clinical trials in the last 30 days; 19. The researchers considered that the subjects had other important diseases that were not suitable for the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glucose tolerance test;Glycosylated hemoglobin;Biochemical series;Blood routine examination;Urine routine test;Vitamin b12;Methyl malonic acid; | — |
Countries
China
Contacts
Public ContactHongyu Kuang
The First Affiliated Hospital of Harbin Medical University
Outcome results
None listed